VC Sofinnova ropes in €650M for biotech, medtech despite 'volatile' environment
Friday, March 27, 2026 · first reported by Fierce Biotech
Sofinnova, a prominent VC firm, has raised €650M (approximately $715M) for its biotech and medtech fund despite volatile market conditions. The fund will focus on early-stage and growth investments in the life sciences sector.
- Firm
- Sofinnova
- Asset class
- Venture
- Geography
- Europe
The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.
Coverage
1 sourceMore on Sofinnova
Everything on this firm →- DIG Ventures raises $120m third fund to target Europe’s AI infrastructure startupsAltAssets +1
- Sofia-based LAUNCHub Ventures secures €65 million first close of Fund III; targets €75 million+EU-Startups +4
- Stride Consumer grows fund 30% with $550m hard-cap close after four-month raiseAltAssets +1
- Forty.5 Ventures Closes a $30M First Fund to Move SEE Founders Onto the World StageThe Recursive
- SEC charges Meyer Global Management, CEO with defrauding investors in SpaceX pre-IPO fundPensions & Investments +1
- Two Google alumni raise $11.3M to back AI startups that enterprises will actually pay forTechCrunch +1